UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of October 2026
Commission
File Number 001-42749
POMDOCTOR
LIMITED
Yongxu
Industrial Park
No.
19-23 Hejing Road, Dongsha Street
Liwan
District, Guangzhou
People’s
Republic of China 510000
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒
Form 20-F ☐ Form 40-F
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
Termination
of American Depositary Receipt Program and Trade Class A Ordinary Shares on Nasdaq
As
previously approved by the board of directors of POMDOCTOR LIMITED (the “Company”) on September 3, 2026 and approved
by the Company’s shareholders on a non-binding advisory basis at the extraordinary general meeting of shareholders held on September
30, 2026, the Company today announced that it has commenced to terminate its American Depositary Receipt program (the “ADR Program”),
including the termination of the related deposit agreement, as amended, and list the Company’s Class A ordinary shares directly
on The Nasdaq Stock Market LLC (“Nasdaq”). The ADR Program to be terminated was established pursuant to the Deposit
Agreement, dated October 9, 2025, as amended, among the Company, Citibank, N.A. (the “Depositary”) and the holders
and beneficial owners of the American Depositary Shares (“ADSs”) issued thereunder (the “Deposit Agreement”).
The
ADR Program and the Deposit Agreement are expected to terminate prior to the opening of the market on October 21, 2026. At that time,
the Company’s ADSs will be mandatorily cancelled and exchanged for the Class A ordinary shares to be distributed to the ADS holders
(the “Mandatory Exchange”) according to the Deposit Agreement.
Simultaneously with the effectiveness of the termination of the ADR Program, the Company will effect a share consolidation of its Class
A ordinary shares and Class B ordinary shares, pursuant to which every ten (10) ordinary shares of each class will be consolidated into
one (1) ordinary share of the same class (the “Share Consolidation”). As a result of the Share Consolidation and Mandatory
Exchange, each holder of ten (10) ADSs will receive three (3) post-Share Consolidation Class A ordinary shares. In connection with the
termination of the ADR Program and Share Consolidation, the Company plans to list its Class A ordinary shares for trading on Nasdaq in
substitution for the ADSs. The Company’s Class A ordinary shares are expected to commence trading on Nasdaq when the market opens
on October 21, 2026 under the symbol “POM” with the new CUSIP number G7166T112.
The
Company has appointed TranShare Corporation as its transfer agent in the United States for its Class A ordinary shares.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
| |
POMDOCTOR
LIMITED |
| |
|
| |
By: |
/s/
Zhenyang Shi |
| |
Name: |
Zhenyang Shi |
| |
Title: |
Chairman and Chief Executive
Officer |
Date:
October 19, 2026